Skip to Main Content

Paper Details

Correction: Activation of RAS/MAPK pathway confers MCL-1 mediated acquired resistance to BCL-2 inhibitor venetoclax in acute myeloid leukemia.
Signal Transduct Target Ther
3
2022
Author NameAffiliation
Haijiao ZhangKnight Cancer Institute, Oregon Health & Science University
Stephen E KurtzKnight Cancer Institute, Oregon Health & Science University
Courtney D DiNardoThe University of Texas MD Anderson Cancer Center
Aaron D SchimmerThe University of Texas MD Anderson Cancer Center
  • 1 - 4

Datasets

Release 1.2